Julian Downward

Q: What Schools Are Affiliated With Julian Downward

Julian Downward is affiliated with the following schools: University of Cambridge, Institute of Cancer Research, University of Bath, Imperial College London, University of Oxford, Utrecht University, Massachusetts Institute of Technology, University of Birmingham

Julian Downward's AcademicInfluence.com Rankings

Julian Downward

Biology

#3090

World Rank

#4777

Historical Rank

Biochemistry

#350

World Rank

#420

Historical Rank

biology Degrees

Download Badge

Biology

Julian Downward's Degrees

Bachelors Biochemistry University of Oxford
PhD Biochemistry University of Oxford

Why Is Julian Downward Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David Julian Harry Downward FRS FMedSci is Associate Research Director at the Francis Crick Institute and Senior Group Leader at the Institute of Cancer Research. He was formerly head of the Signal transduction Laboratory at the London Research Institute. He is a member of the Editorial Board for Cell.

(See a Problem?)

Julian Downward's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. (2012) (5741)
Targeting RAS signalling pathways in cancer therapy (2003) (3106)
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells (1984) (2426)
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences (1984) (2385)
Phosphatidylinositol-3-OH kinase direct target of Ras (1994) (2000)
Mechanisms and consequences of activation of protein kinase B/Akt. (1998) (1382)
Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB (1997) (1238)
Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras (1997) (1127)
Matrix adhesion and Ras transformation both activate a phosphoinositide 3‐OH kinase and protein kinase B/Akt cellular survival pathway (1997) (1126)
Epidermal growth factor regulates p21 ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor (1993) (1001)
PI 3-kinase, Akt and cell survival. (2004) (805)
Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. (2003) (771)
PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. (1997) (748)
Stimulation of p21ras upon T-cell activation (1990) (734)
Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro (1993) (694)
RAS Interaction with PI3K: More Than Just Another Effector Pathway. (2011) (635)
Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis (2002) (622)
Autophosphorylation sites on the epidermal growth factor receptor (1984) (621)
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients (1992) (621)
Expression cloning and characterization of the TGF-β type III receptor (1991) (617)
PINK1-Associated Parkinson's Disease Is Caused by Neuronal Vulnerability to Calcium-Induced Cell Death (2009) (614)
Navigating gene expression using microarrays — a technology review (2001) (600)
Activation of phosphoinositide 3‐kinase by interaction with Ras and by point mutation. (1996) (598)
The Serine Protease Omi/HtrA2 Regulates Apoptosis by Binding XIAP through a Reaper-like Motif* (2002) (590)
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. (2005) (576)
Ras signalling and apoptosis. (1998) (565)
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice (2007) (554)
Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. (2002) (521)
The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1 (2007) (493)
Minimizing the risk of reporting false positives in large-scale RNAi screens (2006) (454)
Multiple Ras Effector Pathways Contribute to G1Cell Cycle Progression* (1999) (440)
PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP (2005) (419)
Chromosomal instability confers intrinsic multidrug resistance. (2011) (400)
Neuroprotective Role of the Reaper-Related Serine Protease HtrA2/Omi Revealed by Targeted Deletion in Mice (2004) (393)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA (2017) (386)
p110δ, a novel phosphoinositide 3-kinase in leukocytes (1997) (374)
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. (2007) (368)
Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine‐dependent growth of hematopoietic cells (1999) (361)
Guidelines for the use of cell lines in biomedical research (2014) (327)
PINK1 Is Necessary for Long Term Survival and Mitochondrial Function in Human Dopaminergic Neurons (2008) (311)
Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. (1996) (311)
Identification of Novel Isoforms of the BH3 Domain Protein Bim Which Directly Activate Bax To Trigger Apoptosis (2002) (309)
Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. (2000) (308)
Akt/PKB localisation and 3′ phosphoinositide generation at sites of epithelial cell–matrix and cell–cell interaction (1999) (301)
Role of Phosphoinositide 3-Kinase in Activation of Ras and Mitogen-Activated Protein Kinase by Epidermal Growth Factor (1999) (299)
Intramolecular and Intermolecular Interactions of Protein Kinase B Define Its Activation In Vivo (2007) (299)
The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. (2000) (285)
Analysis of the transcriptional program induced by Raf in epithelial cells (2001) (278)
Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3‐kinase (1998) (264)
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer (2012) (262)
Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain (2002) (260)
Chromosomal instability determines taxane response (2009) (256)
A complex of Grb2 adaptor protein, Sos exchange factor, and a 36-kDa membrane-bound tyrosine phosphoprotein is implicated in ras activation in T cells. (1994) (253)
Hmga2 functions as a competing endogenous RNA to promote lung cancer progression (2013) (252)
RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms (2013) (248)
How BAD phosphorylation is good for survival (1999) (242)
R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways (1997) (239)
Vav1 Transduces T Cell Receptor Signals to the Activation of Phospholipase C-γ1 via Phosphoinositide 3-Kinase-dependent and -independent Pathways (2002) (233)
Phosphoinositide 3-Kinase Induces Scattering and Tubulogenesis in Epithelial Cells through a Novel Pathway* (1998) (232)
Involvement of FADD and caspase-8 signalling in detachment-induced apoptosis (1999) (219)
Lipid-Regulated Kinases: Some Common Themes at Last (1998) (217)
Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. (1994) (216)
Many faces of Ras activation. (2008) (216)
P110delta, a novel phosphoinositide 3-kinase in leukocytes. (1997) (215)
The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel (2007) (207)
Autophosphorylation and protein kinase C phosphorylation of the epidermal growth factor receptor. Effect on tyrosine kinase activity and ligand binding affinity. (1985) (203)
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs (2011) (197)
The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. (2005) (195)
The ins and outs of signalling (2001) (188)
The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma (2018) (182)
WNT5A--target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. (2007) (178)
The GRB2/Sem‐5 adaptor protein (1994) (174)
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. (2014) (173)
Involvement of Shc in insulin- and epidermal growth factor-induced activation of p21ras (1994) (172)
Evaluation of epidermal growth factor receptors in bladder tumours. (1987) (171)
Control of ras activation. (1996) (171)
The ras superfamily of small GTP-binding proteins. (1990) (168)
Induction of Mxi1-SRα by FOXO3a Contributes to Repression of Myc-Dependent Gene Expression (2007) (167)
CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. (2005) (166)
Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response (2009) (165)
Rictor is a novel target of p70 S6 kinase-1 (2010) (164)
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies (2012) (163)
EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2 (1997) (163)
Role of protein kinase C in T-cell antigen receptor regulation of p21ras: evidence that two p21ras regulatory pathways coexist in T cells (1992) (159)
Raf plus TGFβ-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin (2006) (158)
Murine Ksr interacts with MEK and inhibits Ras-induced transformation (1998) (156)
RASSF1A Interacts with Microtubule-Associated Proteins and Modulates Microtubule Dynamics (2004) (156)
p21ras mediates control of IL‐2 gene promoter function in T cell activation. (1992) (154)
FGF‐2 protects small cell lung cancer cells from apoptosis through a complex involving PKCε, B‐Raf and S6K2 (2006) (151)
Vav3 Modulates B Cell Receptor Responses by Regulating Phosphoinositide 3-Kinase Activation (2002) (150)
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. (2013) (148)
Interactions of Cbl with Two Adaptor Proteins, Grb2 and Crk, upon T Cell Activation (*) (1996) (147)
Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer (2011) (144)
Human Phosphoinositide 3-Kinase C2β, the Role of Calcium and the C2 Domain in Enzyme Activity* (1998) (143)
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize? (2015) (142)
Matrix detachment induces caspase-dependent cytochrome c release from mitochondria: inhibition by PKB/Akt but not Raf signalling (2000) (141)
Activated R-Ras, Rac1, Pi 3-Kinase and Pkcε Can Each Restore Cell Spreading Inhibited by Isolated Integrin β1 Cytoplasmic Domains (2000) (139)
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. (2006) (135)
Expression cloning and characterization of the TGF-beta type III receptor. (1991) (133)
Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance (2013) (132)
A Function for Phosphatidylinositol 3-Kinase β (p85α-p110β) in Fibroblasts during Mitogenesis: Requirement for Insulin- and Lysophosphatidic Acid-Mediated Signal Transduction (1998) (129)
Regulatory mechanisms for ras proteins (1992) (127)
Role of RAS in the regulation of PI 3-kinase. (2010) (126)
Heregulin Induces Phosphorylation of BRCA1 through Phosphatidylinositol 3-Kinase/AKT in Breast Cancer Cells* (1999) (125)
Lack of Correlation between Activation of Jun–NH2-terminal Kinase and Induction of Apoptosis after Detachment of Epithelial Cells (1997) (124)
ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1 (2014) (123)
Role of Bim in the survival pathway induced by Raf in epithelial cells (2004) (122)
Binding Specificity and Regulation of the Serine Protease and PDZ Domains of HtrA2/Omi* (2003) (121)
Tyr-716 in the platelet-derived growth factor beta-receptor kinase insert is involved in GRB2 binding and Ras activation (1994) (121)
PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines (2013) (119)
Mechanism of Epidermal Growth Factor Regulation of Vav2, a Guanine Nucleotide Exchange Factor for Rac* (2003) (117)
Cell cycle: Routine role for Ras (1997) (117)
Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos. (1995) (114)
Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells (2010) (113)
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer (2019) (112)
Monitoring conformational changes of proteins in cells by fluorescence lifetime imaging microscopy. (2003) (112)
Fibroblast Growth Factor 2-Mediated Translational Control of IAPs Blocks Mitochondrial Release of Smac/DIABLO and Apoptosis in Small Cell Lung Cancer Cells (2003) (111)
Protein Kinase B Activation and Lamellipodium Formation Are Independent Phosphoinositide 3-Kinase-Mediated Events Differentially Regulated by Endogenous Ras (1998) (109)
Epidermal growth factor regulates the exchange rate of guanine nucleotides on p21ras in fibroblasts (1993) (108)
Association of Nck with tyrosine‐phosphorylated SLP‐76 in activated T lymphocytes (1999) (108)
Roles of cortactin in tumor pathogenesis. (2007) (106)
Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling (2006) (106)
Identification of a nucleotide exchange-promoting activity for p21ras. (1990) (105)
Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. (2005) (104)
Interaction of Ras with phosphoinositide 3-kinase gamma. (1997) (99)
Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. (2003) (98)
Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells. (2005) (98)
The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth (1999) (95)
The small GTP-binding protein R-Ras can influence integrin activation by antagonizing a Ras/Raf-initiated integrin suppression pathway. (1999) (94)
Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. (2002) (91)
A Role for p38 Stress-Activated Protein Kinase in Regulation of Cell Growth via TORC1 (2009) (90)
The regulation and function of p21ras in T cells. (1992) (90)
Phosphatidylinositol 3' kinase: one of the effectors of Ras. (1996) (89)
Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK1 independently from Parkin (2009) (88)
Antibodies to the autophosphorylation sites of the epidermal growth factor receptor protein‐tyrosine kinase as probes of structure and function. (1985) (87)
SH3 domains of the adapter molecule Grb2 complex with two proteins in T cells: the guanine nucleotide exchange protein Sos and a 75-kDa protein that is a substrate for T cell antigen receptor-activated tyrosine kinases. (1994) (87)
Phosphoinositide 3-Kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. (2006) (85)
An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis (2011) (85)
Identification of the E1A-Regulated Transcription Factor p120E4F as an Interacting Partner of the RASSF1A Candidate Tumor Suppressor Gene (2004) (84)
Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis (2019) (84)
p21ras function is important for T cell antigen receptor and protein kinase C regulation of nuclear factor of activated T cells. (1993) (82)
Role of Shc in the activation of Ras in response to epidermal growth factor and nerve growth factor. (1994) (82)
Paracrine signalling during ZEB1-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in lung fibrosis (2018) (82)
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer (2012) (79)
Chromosomal Instability, Colorectal Cancer and Taxane Resistance (2006) (79)
RNA interference (2004) (78)
Ras and Phosphoinositide 3-Kinase: Partners in Development and Tumorigenesis (2007) (78)
Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway (2002) (77)
Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells (2019) (76)
Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis (2006) (75)
The growth factor IL-2 activates p21ras proteins in normal human T lymphocytes. (1992) (74)
Epithelial to Mesenchymal Transition in Madin-Darby Canine Kidney Cells Is Accompanied by Down-regulation of Smad3 Expression, Leading to Resistance to Transforming Growth Factor-β-induced Growth Arrest* (2003) (74)
The transcriptional response to Raf activation is almost completely dependent on Mitogen-activated Protein Kinase Kinase activity and shows a major autocrine component. (2004) (74)
Targeting RAS and PI3K in lung cancer (2008) (74)
Regulation of Akt(ser473) phosphorylation by Choline kinase in breast carcinoma cells (2009) (72)
Identification of the Ras GTPase-activating protein GAP1m as a phosphatidylinositol-3,4,5-trisphosphate-binding protein in vivo (1999) (71)
Upregulation of two BH3-only proteins, Bmf and Bim, during TGFβ-induced apoptosis (2007) (71)
A target for Pl(3) kinase (1995) (71)
Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis. (2007) (69)
Cancer biology: Signatures guide drug choice (2006) (68)
RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance (2019) (67)
SnapShot: Ras Signaling (2008) (66)
RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. (2014) (64)
Requirement for Interaction of PI3-Kinase p110 alpha with RAS in Lung Tumor Maintenance (2013) (59)
The Grb2 binding domain of mSos1 is not required for downstream signal transduction (1995) (58)
Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase (1998) (58)
Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells (2004) (56)
Regulating 56 kinase (1994) (56)
Suppression of Egr‐1 transcription through targeting of the serum response factor by oncogenic H‐Ras (2006) (56)
CD2 antigen mediated activation of the guanine nucleotide binding proteins p21ras in human T lymphocytes. (1991) (56)
p21ras-induced responsiveness of phosphatidylinositol turnover to bradykinin is a receptor number effect. (1988) (55)
Farnesylation of Ras is important for the interaction with phosphoinositide 3-kinase gamma. (1999) (55)
Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer. (2014) (55)
Involvement of survival motor neuron (SMN) protein in cell death. (2002) (55)
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach (2015) (55)
KSR: A novel player in the RAS pathway (1995) (54)
Distinct Mechanisms of α5β1 Integrin Activation by Ha-Ras and R-Ras* (2000) (54)
Role of phosphoinositide-3-OH kinase in Ras signaling. (1997) (53)
CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid‐specific cancer cell death through autophagy induction (2012) (52)
Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells (2016) (50)
Accumulation of HtrA2/Omi in Neuronal and Glial Inclusions in Brains With &agr;-Synucleinopathies (2008) (49)
Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer (2004) (49)
Role of receptor tyrosine kinases in G-protein-coupled receptor regulation of Ras: transactivation or parallel pathways? (2003) (49)
PI3-kinase p110α mediates β1 integrin-induced Akt activation and membrane protrusion during cell attachment and initial spreading. (2010) (48)
RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression (2016) (48)
The effector loop and prenylation site of R-Ras are involved in the regulation of integrin function (2000) (48)
Prelude to an Anniversary for the RAS Oncogene (2006) (48)
Full Oncogenic Activities of v-Src Are Mediated by Multiple Signaling Pathways (2000) (48)
Requirement of multiple SH3 domains of Nck for ligand binding. (1999) (47)
The mitochondrial protease HtrA 2 is regulated by Parkinson ’ s disease associated kinase PINK 1 (2007) (47)
AKT signalling selectively regulates PINK1 mitophagy in SHSY5Y cells and human iPSC-derived neurons (2018) (46)
Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway. CORRELATION WITH RESISTANCE TO ETOPOSIDE-INDUCED APOPTOSIS. (2002) (46)
Transfer of functional EGF receptors to an IL3‐dependent cell line (1988) (45)
Cell biology: Metabolism meets death (2003) (45)
Signal transduction: New exchange, new target (1998) (45)
Regulation of p21ras by GTPase activating proteins and guanine nucleotide exchange proteins. (1992) (45)
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets (2010) (44)
A function for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in fibroblasts during mitogenesis: requirement for insulin- and lysophosphatidic acid-mediated signal transduction. (1998) (44)
Signal transduction. A target for PI(3) kinase. (1995) (41)
Praf2 Is a Novel Bcl-xL/Bcl-2 Interacting Protein with the Ability to Modulate Survival of Cancer Cells (2010) (40)
Chemokines Fail to Up-Regulate β1 Integrin-Dependent Adhesion in Human Th2 T Lymphocytes1 (2000) (40)
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors (2017) (40)
The structure and function of the epidermal growth factor receptor studied by using antisynthetic peptide antibodies (1985) (40)
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers (2019) (39)
Correction: PINK1 Is Necessary for Long Term Survival and Mitochondrial Function in Human Dopaminergic Neurons (2008) (35)
Networks of interaction of p120cbl and p130cas with Crk and Grb2 adaptor proteins. (1996) (35)
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer (2015) (35)
Rac and Rho in tune (1992) (34)
Flicking the Warburg switch-tyrosine phosphorylation of pyruvate dehydrogenase kinase regulates mitochondrial activity in cancer cells. (2011) (34)
c-Myc induces cytochrome c release in Rat1 fibroblasts by increasing outer mitochondrial membrane permeability in a Bid-dependent manner (2003) (33)
YAP and p73: a complex affair. (2008) (32)
Stimulation of gene expression in neonatal rat ventricular myocytes by Ras is mediated by Ral guanine nucleotide dissociation stimulator (Ral.GDS) and phosphatidylinositol 3-kinase in addition to Raf. (1998) (31)
Modulation of Cellular Migration and Survival by c-Myc through the Downregulation of Urokinase (uPA) and uPA Receptor (2010) (31)
Analysis of gene expression by microarrays: cell biologist's gold mine or minefield? (2000) (31)
Enhanced HtrA2/Omi expression in oxidative injury to retinal pigment epithelial cells and murine models of neurodegeneration. (2009) (31)
Tumour-suppression function of KLF12 through regulation of anoikis (2015) (30)
The protease inhibitor Ucf-101 induces cellular responses independently of its known target, HtrA2/Omi (2006) (30)
Frank-ter Haar Syndrome Protein Tks4 Regulates Epidermal Growth Factor-dependent Cell Migration* (2012) (30)
CUTL1 Is Phosphorylated by Protein Kinase A, Modulating Its Effects on Cell Proliferation and Motility* (2006) (29)
Drugging the Undruggable: Advances on RAS Targeting in Cancer (2021) (29)
Translational responses to growth factors and stress. (2009) (29)
CUTL1: A Key Mediator of TGFβ-Induced Tumor Invasion (2006) (28)
SnapShot: Class I PI3K Isoform Signaling (2013) (28)
IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche (2020) (28)
Functional inhibition of PI3K by the βGBP molecule suppresses Ras–MAPK signalling to block cell proliferation (2007) (27)
a novel phosphoinositide 3-kinase in leukocytes (1997) (27)
Targeting RAF: trials and tribulations (2011) (27)
Genetic and cellular mechanisms of oncogenesis. (2009) (26)
Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors (2018) (26)
Inhibiting the RAS-PI3K pathway in cancer therapy. (2013) (25)
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers (2021) (25)
Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids (2013) (24)
Omi is a mammalian heat-shock protein that selectively binds and detoxifies oligomeric amyloid-β (2009) (24)
Distinct mechanisms of alpha 5beta 1 integrin activation by Ha-Ras and R-Ras. (2000) (24)
RAC1 P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance (2019) (24)
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry (2021) (23)
Exoenzyme S of Pseudomonas aeruginosa is not able to induce apoptosis when cells express activated proteins, such as Ras or protein kinase B/Akt (2006) (23)
RAS's cloak of invincibility slips at last? (2014) (23)
Interleukin (IL)‐2 activation of p21ras in murine myeloid cells transfected with human IL‐2 receptor β chain (1992) (22)
Antibodies to the ATP-binding site of the human epidermal growth factor (EGF) receptor as specific inhibitors of EGF-stimulated protein-tyrosine kinase activity. (1986) (22)
Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer (2008) (22)
Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer (2018) (22)
Regulation of MUC1 expression in human mammary cell lines by the c-ErbB2 and ras signaling pathways. (2001) (22)
Exchange rate mechanisms (1992) (21)
Cancer: A tumour gene's fatal flaws (2009) (21)
HF‐Free Boc Synthesis of Peptide Thioesters for Ligation and Cyclization (2016) (21)
Viral pro-survival proteins block separate stages in Bax activation but changes in mitochondrial ultrastructure still occur (2008) (20)
Ras activation of phosphatidylinositol 3-kinase and Akt. (2001) (20)
Measurement of nucleotide exchange and hydrolysis activities in immunoprecipitates. (1995) (19)
Plugging the GAPs (1991) (19)
Fibroblast Growth Factor-2 Induces Translational Regulation of Bcl-XL and Bcl-2 via a MEK-dependent Pathway (2002) (19)
RNA Interference Libraries Prove Their Worth in Hunt for Tumor Suppressor Genes (2005) (19)
SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity (2019) (19)
Correction: PINK1 Is Necessary for Long Term Survival and Mitochondrial Function in Human Dopaminergic Neurons (2008) (18)
Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers (2021) (18)
Ras regulation: putting back the GTP (1992) (17)
Apoptosis: Ras to the rescue in the fly eye (1999) (17)
Initiation of High Frequency Multi-Drug Resistance Following Kinase Targeting by siRNAs (2007) (16)
JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer (2021) (16)
RAS mutation status and bortezomib therapy for relapsed multiple myeloma (2015) (16)
Unraveling the complexity of endocrine resistance in breast cancer by functional genomics. (2008) (16)
CUTL1: a key mediator of TGFbeta-induced tumor invasion. (2006) (15)
Combined targeting of G protein‐coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN‐null triple negative breast cancer (2020) (15)
Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer (2016) (15)
Mutant KRAS at the Heart of Tumor Immune Evasion. (2020) (15)
Bidirectional epithelial–mesenchymal crosstalk provides self-sustaining profibrotic signals in pulmonary fibrosis (2021) (14)
LBA1 Mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: Towards molecular cancer prevention (2022) (14)
Measurements of GTP/GDP exchange in permeabilized fibroblasts. (1995) (13)
Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor (2016) (13)
Proteolytic generation of constitutive tyrosine kinase activity of the human insulin receptor. (1989) (12)
Identification of the E 1 A-Regulated Transcription Factor p 120 E 4 F as an Interacting Partner of the RASSF 1 A Candidate Tumor Suppressor Gene (2004) (11)
Retraction: HMGA2 functions as a competing endogenous RNA to promote lung cancer progression (2015) (11)
Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance (2020) (11)
Structure of human epidermal growth factor receptor and expression of normal and variant mRNAs in epidermoid carcinoma cells (1985) (11)
Evidence That STK19 Is Not an NRAS-dependent Melanoma Driver (2020) (11)
RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy? (2004) (10)
WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer (2020) (10)
Overview of KRAS‐Driven Genetically Engineered Mouse Models of Non‐Small Cell Lung Cancer (2015) (10)
An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations. (2022) (10)
Finding the weakness in cancer. (2009) (10)
T lymphocyte activation signals. (1992) (9)
ATMIN is a tumor suppressor gene in lung adenocarcinoma. (2019) (9)
RNA interference-based functional genomics in cancer research – an introduction (2004) (9)
Signal transduction. Regulating S6 kinase. (1994) (9)
Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets (2020) (8)
Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer (2021) (8)
Identification of the Ras GTPase-activating protein GAP1m as an in vivo phosphatidylinositol 3,4,5-trisphosphate-binding protein (1999) (7)
How to fool a wonder drug: truncate and dimerize. (2012) (7)
Regulation of p21ras by GTPase activating proteins and guanine nucleotide exchange proteins (1992) (7)
Structural and functional features of a cell surface phosphoglycoprotein associated with tumorigenic phenotype in human fibroblast x HeLa cell hybrids. (1986) (7)
Ras activation revisited (2001) (6)
Influence of p21ras on phosphatidylinositol turnover. (1988) (6)
Interaction of Ras with phosphoinositide 3-kinase c (1997) (5)
RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma (2022) (5)
Abstract A54: Requirement for interaction of PI 3-kinase p110alpha with Ras in lung tumor maintenance (2013) (5)
APOBEC3B expression generates an immunogenic model of Kras mutant lung cancer (2020) (5)
Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma (2021) (4)
The Protein Kinase Facts Book (Parts I and II) (1996) (4)
Characterisation of tumour immune microenvironment remodelling following oncogene inhibition in preclinical studies using an optimised imaging mass cytometry workflow (2021) (4)
Soft is strong (2009) (4)
Concordance of exon array and real-time PCR assessment of gene expression following cancer cell cytotoxic drug exposure (2008) (4)
Human PI 3-Kinase C2á - the Role of Calcium and the C2 Domain in Enzyme Activity (1998) (3)
Lung adenocarcinoma promotion by air pollutants (2023) (3)
Antibodies against endogenous retroviruses promote lung cancer immunotherapy (2023) (3)
Abstract 964: Intra-tumor heterogeneity and Darwinian selection revealed by multi-region exome sequencing of renal cell carcinomas (2012) (3)
Quantitative Proteomic Analysis in Alveolar Type II Cells Reveals the Different Capacities of RAS and TGF-β to Induce Epithelial–Mesenchymal Transition (2021) (3)
Corrigendum to “PI3-kinase p110α mediates β1 integrin-induced Akt activation and membrane protrusion during cell attachment and initial spreading” [Cell. Signal. 22 (2010) 1838–1848] (2012) (2)
Update on The Big C: complexity and cross-talk between pathways (2002) (2)
Micro-CT acquisition and image processing to track and characterize pulmonary nodules in mice (2022) (2)
Cancer Therapy : Preclinical PI 3 K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines (2013) (2)
The Use of Anti-Synthetic Peptide Antibodies to Study the v-erb B Protein from Chicken and Rat Cells Transformed by Avian Erythroblastosis Virus (1985) (2)
Evaluation ofepidermal growth factor receptors inbladder tumours (1987) (2)
Inherited duplications of PPP2R3B predispose to nevi and melanoma via a C21orf91-driven proliferative phenotype (2021) (1)
Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway. Correlation with resistance to etoposide-induced apoptosis. (2015) (1)
Assessing cell size and cell cycle regulation in cells with altered TOR activity. (2012) (1)
A Functional Role for CERT in Cancer Drug Induced Autophagy and Prognosis in Her2 Positive Breast Cancer. (2009) (1)
Abstract A17: Loss of DEPTOR increases resistance to EGFR tyrosine kinase inhibitors by upregulating EGFR and MAPK signaling (2012) (1)
Abstract P111: Therapeutic KRASG12C inhibition alleviates KRAS-driven immunosuppression (2021) (1)
15 Identification of new combination therapies for lung cancer tumours harbouring KRAS mutations (2018) (1)
Signal transduction. Rac and Rho in tune. (1992) (1)
The GTPase superfamily (Ciba foundation symposium 176): edited by Joan Marsh and Jamie Goode, John Wiley, 1993, £45.00 (289 pages) ISBN 0 471 93914 5 (1994) (1)
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition (2022) (1)
Targeting a KRAS neoantigen peptide vaccine to DNGR-1+ dendritic cells (2020) (1)
220 Identification of resistance mechanisms to EGFR inhibitors in non-small cell lung cancer cells (2010) (1)
Abstract A26: GATA2 is necessary for oncogene-mutant non-small cell lung tumorigenesis (2012) (1)
Differential toxicity in an alveolar epithelial cell line of fine particulate matter from brakewear, roadwear, and diesel exhaust (2022) (1)
Simultaneous EGFR mutation detection and copy number assessment in circulating tumour DNA (ctDNA) to inform molecular methods of therapy resistance and plasma ctDNA content in lung adenocarcinoma. (2016) (1)
Frank-ter Haar syndrome protein Tks 4 regulates EGF-dependent cell migration (2012) (1)
Abstract 4029: Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor immunity (2022) (1)
Signal transduction. Exchange rate mechanisms. (1992) (1)
IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche (2020) (1)
An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations (2022) (1)
The Role of PI3-Kinase in the Regulation of Cell Survival and Apoptosis (1999) (1)
Faculty Opinions recommendation of Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. (2003) (1)
Regulators of Mitotic Transition Determine Paclitaxel Resistance In Vitro and Predict Poor Prognosis in Breast Cancer In Vivo. (2009) (1)
Trachealess--a new transcription factor target for PKB/Akt. (2001) (1)
3 EGFR mutant circulating tumour DNA detection in advanced lung adenocarcinoma: optimising the application of a ctDNA diagnostic to real world clinical practice (2016) (1)
Stratification method based on RAS pathway oncogenic activity predicts outcome in lung adenocarcinoma (2020) (0)
Abstract PR14: Targeting the GATA2 transcriptional network in K-Ras driven lung adenocarcinoma (2013) (0)
Chromosomal instability determines taxane sensitivity - supplementary materials (2009) (0)
Abstract SY25-02: Synthetic lethal approaches to targeting RAS mutant tumors: Is there an Achilles' heel. (2013) (0)
Abstract 2987: Identification of new combination therapies for lung tumors harboring KRAS mutations (2018) (0)
Abstract 1820: Uncovering mechanisms of immune evasion in a novel immunogenic model of KRAS-mutant lung cancer (2021) (0)
5 - mTORC2: The Other Facet of mTOR (2010) (0)
The Potency of a KRAS Silent Variant. (2022) (0)
Abstract IA20: The impact of RAS inhibition on tumor immune evasion (2023) (0)
Inherited duplications of PPP2R3B promote naevi and melanoma via a novel C21orf91-driven proliferative phenotype (2019) (0)
222 POSTER RNAi screen for Akt regulator (2008) (0)
Genome-Wide siRNA Screen for Anti-Cancer Drug Resistance in Adherent Cell Lines (2015) (0)
Abstract B016: High throughput application of the NanoBiT Biochemical Assay for the discovery of selective p110α isoform binders that block its interaction with KRAS (2023) (0)
Abstract IA06: Oncogenic Ras control of the tumor immune microenvironment (2020) (0)
A Functional Metagene Incorporating TTK Protein Kinase, Aurora Kinase B and Glucosylceramide Synthase Predicts Response to Treatment in Primary Breast Cancer (2009) (0)
Characterisation of PINK1 knockout mice (2009) (0)
Identification and characterisation of cyclic peptide inhibitors of Ras/p110α and Ras/Raf protein complexes (2015) (0)
Identification of new combination therapies for NSCLC tumours harbouring KRAS mutations (2016) (0)
Abstract IA12: Targeting unique dependencies of RAS mutant tumors. (2012) (0)
354 Exploration of the Role of Ras–PI3K Interaction in Lung Tumor Maintenance (2012) (0)
Abstract 3105: Chromosome 18q encodes a chromosomal instability suppressor locus in colorectal cancer (2012) (0)
Abstract B073: Development of combination therapies to potentiate the impact of KRAS-G12C inhibitors in lung cancer (2019) (0)
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers (2019) (0)
ANALYSIS OF CELL TRANSFORMATION BY ONCOGENIC RAS USING NOVEL FUNCTIONAL GENOMICS APPROACHES (2005) (0)
Abstract A18: Reduced NF1 expression in resistance to EGF receptor inhibitory drugs in lung adenocarcinoma (2012) (0)
Abstract 1926: Machine learning-enhanced image and spatial analytic pipelines for imaging mass cytometry applied to the TRACERx non-small cell lung cancer study (2022) (0)
Small and interfering (2005) (0)
Ras to raf to MAPKK (1993) (0)
509 Immune checkpoint blockade boosts anti-tumour B cell responses in lung adenocarcinoma (2022) (0)
Abstract 4472: PI3K pathway dependencies in endometrioid endometrial cancer. (2013) (0)
Abstract 4155: The RAF/MEK clamp avutometinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1 (2023) (0)
Abstract A169: The role of the RAS-PI3K interaction in tumor maintenance and metastasis. (2011) (0)
Automated segmentation of murine lung tumors in x-ray micro-CT images (2014) (0)
Abstract B19: New tools to study the role of RAS/CRAF interaction in RAS-driven lung cancer (2020) (0)
binding and Ras activation. beta-receptor kinase insert is involved in GRB2 Tyr-716 in the platelet-derived growth factor (2013) (0)
RNAi and 2DE, a promising combination for analysis of phospho-signalling and substrate identification (2006) (0)
13 Molecular profiling of non-small cell lung cancer (NSCLC) – the liquid biopsy comes of age (2014) (0)
Abstract 2197: Targeted cancer therapy induces APOBEC fueling the evolution of drug resistance (2022) (0)
Multiple pathways for the regulation of p21ras in T lymphocytes (1992) (0)
Phosphatidylinositol 3' Kinase: One of the Effectors of Ras: Discussion (1996) (0)
Abstract 1352: In vivo CRISPR screening identifies mediators of immune evasion in KRAS-mutant lung cancer (2022) (0)
Transformation by the mSos1 Ras exchange protein. (1994) (0)
Abstract 4835: Genetic determinants of mTOR inhibitor response in breast and endometrial cancer (2012) (0)
128 Investigation of RAS and PI 3-kinase signaling networks in cancer using synthetic lethal screens (2009) (0)
Abstract LB-356: An siRNA screen identifies Rsk1 as a key modulator of lung cancer metastasis (2011) (0)
Abstract A160: Deep immunoprofiling of mouse lung cancer models in steady state and upon drug treatment. (2019) (0)
RoleofProtein KinaseC inT-Cell Antigen Receptor Regulation ofp2lras: Evidence thatTwo p2lras Regulatory Pathways Coexist inT Cells (1992) (0)
474 Inherited duplications of PPP2R3B promote naevi and melanoma via a novel C21orf91-driven proliferative phenotype (2019) (0)
Palmitoyl transferase ZDHHC20 promotes pancreatic cancer metastasis (2023) (0)
G proteins, Ras and cancer (1996) (0)
Fibroblast Growth Factor 2-Mediated Translational Control of IAPs Blocks Mitochondrial Release of Smac/DIABLO and Apoptosis in Small Cell Lung Cancer Cells (2004) (0)
Tyrosine kinases to Ras (1993) (0)
RSK1 is a key regulator of lung cancer metastasis (2011) (0)
In vivo CRISPR screen identifies KRAS-induced COX-2 as a driver of immune evasion and immunotherapy resistance in lung cancer (2023) (0)
Abstract 5733: Combining KRASG12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer (2023) (0)
Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumour immunity (2022) (0)
Abstract LB124: APOBEC3B fuels evolution of resistance during targeted cancer therapy (2021) (0)
Abstract P026: Uncovering mechanisms of immune evasion in a novel immunogenic model of KRAS-mutant lung cancer (2022) (0)
RNAi and cancer research: The path to a cure? (2004) (0)
9 Mechanisms of transformation by RAS oncogenes: searching for novel therapeutic approaches (2012) (0)
Paracrine signalling during ZEB1-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in lung fibrosis (2018) (0)
20 Identification of combinatorial therapies with inhibitors of the PI3K pathway in PTEN-null tumours (2018) (0)
Correction: WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer (2021) (0)
Long sought-after guanine nucleotide exchange factors for Ras-like proteins have now been cloned in mammals and in Drosophila: one is encoded by a known oncogene. (1992) (0)
The structure and function of the receptor for epidermal growth factor (1986) (0)
Abstract 1390: Immunotherapy boosts B cell responses in lung adenocarcinoma (2022) (0)
RNAi and 2DE, a promising combination for analysis of phospho-signalling and substrate identification (2003) (0)
Abstract B221: Hmga2 furthers lung adenocarcinoma progression through function as a competing endogenous RNA. (2013) (0)
current as proteins in normal human T lymphocytes . The growth factor IL-2 activates p 21 ras (2001) (0)
PI 108, A novel human phosphoinositide 3-kinase (1996) (0)
PINK1 is necessary for long term survival and mitochondrial function in primary human dopaminergic neurons (2009) (0)
Erratum: Strategies for cutting carbon (1998) (0)
Coupling of ras to the T Cell Antigen Receptor (1993) (0)
Abstract 6113: Spatially resolved biomarker detection on single cells in TRACERx using multiplex imaging (2022) (0)
AKT signalling selectively regulates PINK1 mitophagy in SHSY5Y cells and human iPSC-derived neurons (2018) (0)
A novel complex comprising BRaf, PKCϵ and S6K2 mediates the pro-survival effects of FGF-2 in small cell lung cancer cells (2007) (0)
O-177 A novel epigenetic mechanism of chemo-resistance in SCLC induced by fibroblast growth factor-2 (FGF-2): dissociation of Smac/DIABLO from cytochrome c release (2003) (0)
Quantitative proteomic analysis in ATII cells reveals the different capacities of 1 RAS and TGF-β to induce EMT 2 (2021) (0)
Investigating the effects of metals within particulate matter in human alveolar epithelial cells (2022) (0)
Abstract 2408: A novel multiplex droplet digital PCR approach to KRAS mutation detection in circulating tumor DNA (2015) (0)
A palmitoyl transferase chemical genetic system to map ZDHHC-specific S-acylation (2023) (0)
Characterisation of a cyclic peptide that binds to the RAS binding domain of phosphoinositide 3-kinase p110α (2023) (0)
Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4 (2023) (0)
Disruption of the Interactio n of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer Graphical (2018) (0)
Abstract 3609: Defining extrinsic and intrinsic mechanisms of immune evasion in TRACERx using imaging mass cytometry (2022) (0)
Abstract LB-398: Identification of novel mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (2011) (0)
Abstract PL04-04: Synthetic lethal approaches to targeting Ras mutant cancers. (2013) (0)
CUTL1–a modulator of tumor cell invasion and target of TGF-beta which is highly expressed in colon cancer (2004) (0)
The Oncogene FactsBook (1995) (0)
Abstract LB-A17: Identification and Characterization of Cyclic Peptide Inhibitors for Ras/PI3K and Ras/Raf Protein Complexes (2018) (0)
1997 Salk Institute/EMBL meeting on Oncogenes and Growth Control, Salk Institute, La Jolla, California, 16-20 August 1997. (1998) (0)
Growth and maturation factors, volume 2, G. Guroff (Ed.), John Wiley & Sons, Chichester, 1984. xiii + 340 pp. incl. index. Price: £66. ISBN 0 471 09708 X (1985) (0)
Abstract B11: RAS orchestrates the increase of interstitial adenosine in lung adenocarcinoma to promote immune evasion (2020) (0)
RAS orchestrates an increase of interstitial adenosine in lung adenocarcinoma to promote immune evasion (2020) (0)
Abstract #LB-277: An siRNA screen identifies RSK family members as key regulator of lung cancer metastasis (2009) (0)
Targeting oncogenic signalling pathways to modulate the lung cancer immune microenvironment (2020) (0)
509 The GATA2 Transcriptional Network is Requisite for Ras Oncogene-driven Non-small Cell Lung Cancer (2012) (0)
Abstract A145: Study of mechanisms of immune evasion of oncogenic KRAS in NSCLC (2019) (0)

This paper list is powered by the following services:

Other Resources About Julian Downward

What Schools Are Affiliated With Julian Downward?

Julian Downward is affiliated with the following schools:

Julian Downward's Academic­Influence.com Rankings